ATTEND THE VIRTUAL POSTER SYMPOSIUM
CLICK HERE to join the 2026 ACCP VPS
Abstract Submission Deadlines
- March 23, 2026 – Submission deadline for all absetracts except Research-in-Progress
- April 21, 2026 – Submission deadline for Research-in-Progress abstracts
- April 28, 2026 – Abstract acceptance notifications sent
About the Virtual Poster Symposium
Investigators in clinical pharmacy and clinical pharmacology—ACCP members and nonmembers—will present their findings during the ACCP Virtual Poster Symposium, May 19 & 20, 2026.
Posters will be available for asynchronous viewing and comment from May 16–24. Two live interactive sessions will be held on May 19 and May 20 from 7:00–9:00 p.m. ET, when authors will be available for real-time Q&A via online chat on their chosen evening. Presenters may also offer live video/audio Q&A using their preferred platform.
Presenters and attendees need only a broadband Internet connection and a current web browser.
All accepted abstracts presented during the symposium—excluding “Encore” and “Research-in-Progress” posters—will have full-text abstracts published online in the Journal of the American College of Clinical Pharmacy (JACCP). Only the abstract title, authors, and original citation will be published for “Encore” presentations.
A non-refundable $50 submission fee applies to each abstract, regardless of acceptance status.
Regular Abstract Submission Categories Closed
Word Limit: This abstract category has a 300 word limit.
Abstract Deadline: Monday March 23, 2026, 11:59 PM Central Time.
Abstracts must describe the development, delivery, justification, or documentation of clinical pharmacy practice, education, or training outside of the United States. Abstracts may be descriptive and do not need to include an evaluative component.
Abstracts must include the following section headers:
- Service or Program
- Justification/Documentation
- Adaptability
- Significance
Reviewers will evaluate abstracts based on:
- Originality of the service or program within the specific setting
- Adequacy of justification and supporting documentation
- Adaptability to other settings
- Significance to international clinical pharmacy advancement
- Overall readability
Word Limit: This abstract category has a 300 word limit.
Abstract Deadline: Monday March 23, 2026, 11:59 PM Central Time.
Abstracts of case reports must update and expand therapeutic insights and possibilities or generate research hypotheses. While narrative in nature, these abstracts must emphasize the evidence supporting the authors’ conclusions by describing:
- The process followed to understand the findings and possible mechanisms involved in the patient’s case
- How the patient was evaluated and treated
- A specific description of the outcome
Abstracts must include the following section headers:
- Introduction
- Case
- Discussion
- Conclusion
Reviewers will evaluate abstracts based on:
- Uniqueness of the report
- Clinical findings presented
- Outcomes documented
- “Take-away” lessons
- Overall readability
(Evaluation is based on the abstract criteria recommended by the CARE Guidelines: CAse REport Group
Reviewers will evaluate abstracts based on:
- Uniqueness of the report
- Clinical findings presented
- Outcomes documented
- “Take-away” lessons
- Overall readability
(Evaluation is based on the abstract criteria recommended by the CARE Guidelines: CAse REport Group http://www.care-statement.org/resources/checklist)
Abstracts of case reports presented elsewhere, but important to clinical pharmacy, are encouraged as "Encore" submissions.
Word Limit: This abstract category has a 300 word limit.
Abstract Deadline: Monday March 23, 2026, 11:59 PM Central Time.
Abstracts must describe the development, delivery, justification, or documentation of new or innovative clinical pharmacy services. Abstracts that address components of the ACCP Standards of Practice for Clinical Pharmacists (see
www.accp.com/standards) and/or describe efforts to develop, advance, or position clinical pharmacists to optimize patient care are encouraged. Abstracts may be descriptive and do not need to include an evaluative component.
Abstracts must include the following section headers:
- Service or Program
- Justification/Documentation
- Adaptability
- Significance
Reviewers will evaluate abstracts based on:
- Originality of the service or program described
- Adequacy of justification and supporting documentation
- Adaptability of the service or program to other settings
- Significance to clinical pharmacy
- Overall readability
- Submission Deadline Closed
- FAQs
Abstract Deadline: Monday March 23, 2026, 11:59 PM Central Time.
Encore presentation are accepted in the Original Research, Systematic Reviews/Meta-Analyses, or Case Reports categories only. Abstracts submitted for the Encore Presentation category must not be modified from the previously presented/published version. This includes the title, authors, and abstract body. The presenting author may change, but the author must be an author on the original abstract.
- Abstracts submitted for Encore Presentations must not be modified from the previously presented/published version. This includes the title, authors, and abstract body. The presenting author may change, but the author must be an author on the original abstract.
- The same abstract may not be presented at more than one national ACCP event.
- Only the abstract title, authors, and original citation will be published in JACCP.
Word Limit: This abstract category has a 300 word limit.
Abstract Deadline: Monday March 23, 2026, 11:59 PM Central Time.
Abstracts must summarize quantitative or qualitative findings from completed research. (Descriptions of planned research efforts or preliminary data will not be accepted.) Acceptable research types include basic, clinical, translational, dissemination/implementation, or educational research. Topics should appeal to a clinical pharmacy audience and may include areas such as:
- Drug metabolism
- Education/pedagogy
- Health services
- Medication safety
- Patient/population outcomes
- Pharmacokinetics and pharmacodynamics
- Pharmacoeconomics and pharmacoepidemiology
- Pharmacogenomics
- Pharmacology or pharmacotherapy
Abstracts reporting in vitro or animal research are welcome.
Abstracts must include the following section headers:
- Introduction
- Research Question or Hypothesis
- Study Design
- Methods
- Results
- Conclusions
Reviewers will evaluate abstracts based on:
- Merit of the research question or hypothesis
- Study design
- Originality
- Methods and data analysis
- Results and conclusions
- Overall readability
Original research findings presented elsewhere, but important to clinical pharmacy, are encouraged as
“Encore” submissions (see Encore Presentation details below). A previously presented abstract may form the basis for a new submission if the prior abstract:
- Was a descriptive report of planned research only
- Reported preliminary results only and complete results are now available
- Was presented at a student, resident, or fellow conference focused on presentation experience and/or formative feedback
- Was presented at an ACCP Chapter or PRN event
- Has conclusions added or modified based on a new hypothesis and data analysis of the original results database
Word Limit: This abstract category has a 300 word limit.
Abstract Deadline: Monday March 23, 2026, 11:59 PM Central Time.
Abstracts must describe a scoping review adhering to the guidelines and definitions established by Preferred Reporting Items for Systematic Reviews and Meta-Analyses for Scoping Reviews (PRISMA-ScR). Please refer to the PRISMA-ScR fillable checklist for more details. You can click here to access the checklist.
Abstracts should highlight the objectives, findings, and implications of the review, emphasizing its contribution to knowledge and identifying gaps for further research. (Note: Scoping reviews are distinct from traditional literature reviews in their broader focus and exploratory nature.)
Abstracts presented elsewhere but important to clinical pharmacy are encouraged as Encore submissions.
Word Limit: This abstract category has a 300 word limit.
Abstract Deadline: Monday March 23, 2026, 11:59 PM Central Time.
Abstracts must describe a systematic review adhering to the guidelines and definitions established by the Preferred Reporting Items for Systematic Reviews and Meta-Analyses
(PRISMA for Abstracts statement) and include the 12 items published in the PRISMA for Abstracts checklist
(PRISMA checklist).
Abstracts must follow the PRISMA for Abstracts format:
- Background
- Methods
- Results
- Discussion
- Other
Reviewers will evaluate abstracts based on the merits of the 12 PRISMA for Abstracts checklist items:
- Title
- Objectives
- Eligibility criteria
- Information sources
- Risk of bias
- Included studies
- Synthesis of results
- Description of the effect
- Strengths and limitations of evidence
- Interpretation
- Funding
- Registration
Abstracts presented elsewhere, but important to clinical pharmacy, are encouraged as "Encore" submissions.
- Submission Deadline Closed
- FAQs
Word Limit: This abstract category has a 300 word limit.
Abstract Deadline: Tuesday April 21, 2026, 11:59 PM Central Time.
Submission guidelines are those of an Original Research abstract except that the research effort is ongoing at the time of abstract submission.
- The presenting author must be in a post-graduate training program (PGY-1 or PGY-2 residency, Ph.D./Masters graduate degree program, or fellowship training program).
- Abstracts submitted in the Research-in-Progress category are not eligible for the Resident and Fellow Best Poster competition. *Note: to be eligible for the Best Poster competition, the research must meet the criteria for and be submitted under the Original Research category, indicating that it was conducted by a resident or fellow.
- In-Progress abstracts will not be published in JACCP.
- Submission Deadline Closed
- FAQs
Word Limit: This abstract category has a 300 word limit.
Abstract Deadline: Tuesday April 21, 2026, 11:59 PM Central Time.
Submission guidelines are those of an Original Research abstract except that the research effort is ongoing at the time of abstract submission.
- The presenting author must be a first professional degree (Pharm.D. or B.S. Pharm.) student.
- Abstracts submitted in the Research-in-Progress category are not eligible for the Student Best Poster competition. *Note: to be eligible for the Best Poster competitions, the research must meet the criteria for and be submitted under the Original Research category, indicating that it was conducted by a student.
- In-Progress abstracts will be not published in JACCP.
Invite Only Abstract Submission Categories Closed
Word Limit: This abstract category has a 300 word limit.
Abstract Deadline: Monday March 23, 2026, 11:59 PM Central Time.
Abstracts must summarize quantitative or qualitative findings from completed research. Basic, clinical, translational, dissemination/implementation, or educational research are examples of acceptable research. Topics should appeal to a clinical pharmacy audience and may include research in drug metabolism, education/pedagogy, health services, medication safety, patient/population outcomes, pharmacokinetics, pharmacodynamics, pharmacoeconomics, pharmacoepidemiology, pharmacogenomics, pharmacology, or pharmacotherapy. Abstracts reporting in vitro or animal research are welcome.
- Abstracts must be structured with the section headers of: Introduction, research question or hypothesis, study design, methods, results, and conclusions.
- Descriptions of planned research efforts or preliminary data will not be accepted.
Word Limit: This abstract category has a 300 word limit.
Abstract Deadline: Friday May 1, 2026, 11:59 PM Central Time.